The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas

Purpose of Investigation: To investigate the presence of 15-lipoxygenase-1 (15-LOX-1) expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas. Materials and Methods: The authors investigated the presence of 15-LOX-1 expression in samples from patients diagnosed with normal endometrium (n = 12), endometrial hyperplasia (n = 12), and endometrial cancer (n = 12). The immunohistochemical stainings were scored by three independent pathologists. A Western blot of 15- LOX-1 determined the presence of protein expression in normal endometrium. A Kolmogorov–Smirnov test was used to evaluate the data's distribution pattern. For pairwise comparisons of the combined scores between groups, the Mann-Whitney U test was used. Results: Based on the combined scores for 15-LOX-1 expression, strong immunochemistry staining was observed in samples diagnosed with normal endometrium. There was a significant difference in 15-LOX-1 expression between normal endometrium and endometrial adenocarcinoma (p = 0.03). Comparing tissues from normal endometrium and endometrial hyperplasia, there was a decline in the expression from normal endometrium to endometrial hyperplasia. However, the difference was not statistically significant. Conclusion: The present results show that a decrease of 15-LOX-1 expression in the endometrial tumorigenesis process, starting from normal endometrium to hyperplasia and endometrial cancer, might be a trigger. Further studies are required to determine its potential use as a marker in a larger randomized multicenter study.

15-LOX-1, Endometrial hyperplasia; Endometrial adenocarcinomas.

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.

[2] Bokhman J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10.

[3] Felix A.S., Weissfeld J.L., Stone R.A., Bowser R., Chivukla A., Edwards R.P., Linkov F.: “Factors associated with Type I and Type II endometrial cancer”. Cancer Causes Control, 2010, 21, 1851.

[4] Kurman R.J., Kaminski P.F., Norris H.J.: “The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients”. Cancer, 1985, 56, 403.

[5] Baer A.N., Costello P.B., Green F.A.: “In vivo activation of an omega-6 oxygenase in human skin”. Biochem. Biophys. Res. Commun., 1991, 180, 98.

[6] Brash A.R., Boeglin W.E., Chang M.S.: “Discovery of a second 15Slipoxygenase in humans”. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 6148.

[7] Serhan C.N., Jain A., Marleau S., Clish C., Kantarci A., Behbehani B., et al.: “Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators”. J. Immunol., 2003, 171, 6856.

[8] Ariel A., Li P.L., Wang W., Tang W.X., Fredman G., Hong S., et al.: “The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering”. J. Biol. Chem., 2005, 280, 43079.

[9] Shureiqi I., Wojno K.J., Poore J.A., Reddy R.G., Moussalli M.J., Spindler S.A., et al.: “Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-ipoxygenase-1 expression in human colon cancers”. Carcinogenesis, 1999, 20, 1985.

[10] Nixon J.B., Kim K.S., Lamb P.W., Bottone F.G., ElingT.E.: “15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer”. Prostaglandins Leukot. Essent. Fatty Acids, 2004, 70, 7.

[11] Heslin M.J., Hawkins A., Boedefeld W., Arnoletti J.P., Frolov A., Soong R., et al.: “Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer”. Ann. Surg., 2005, 241, 941.

[12] Moussalli M.J., Wu Y., Zuo X., Yang X.L., Wistuba I.I., Raso M.G., et al.: “Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion”. Cancer Prev. Res. (Phila.), 2011, 4, 1961.

[13] Shureiqi I., Xu X., Chen D., Lotan R., Morris J.S., Fischer S.M., Lippman S.M.: “Nonsteroidal anti-inflammatory drugs induce apoptosis in esophagealcancer cells by restoring 15-lipoxygenase-1 expression”. Cancer Res., 2001, 61, 4879.

[14] Jiang W.G., Watkins G., Douglas-Jones A., Mansel R.E.: “Reduction ofisoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer”. Prostaglandins Leukot. Essent. Fatty Acids, 2006, 74, 235.

[15] Hennig R., Kehl T., Noor S., Ding X.Z., Rao S.M., Bergmann F., et al.: “15-lipoxygenase-1 production is lost in pancreatic cancer and overex-pression of the gene inhibits tumor cell growth”. Neoplasia, 2007, 9, 917.

[16] Zuo X., Peng Z., Wu Y., Moussalli M.J., Yang X.L., Wang Y., et al.: “Effects of guttargeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice”. J. Natl. Cancer Inst., 2012, 104, 709.

[17] Zuo X., Shen L., Issa J.P., Moy O., Morris J.S., Lippman S.M., Shureiqi I.: “15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation”. FASEB J., 2008, 22, 1981.

[18] Bradford M.: “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding”. Anal. Biochem., 1976, 72, 248.

[19] Boruban M.C., Altundag K., Kilic G.S., Blankstein J.: “From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures”. Eur. J. Cancer Prev., 2008, 17, 133.

[20] Kilic G., Gurates B., Garon J., Kang H., Arun B., Lampley C.E., et al.: “Expression of cyclooxygenase-2 in endometrial adenocarci-noma”. Eur. J. Gynaecol. Oncol., 2005, 26, 271.

[21] Wu Y., Fang B., Yang X.Q., Wang L., Chen D., Krasnykh V., et al.: “Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer”. Mol. Ther., 2008, 16, 886.

[22] Shureiqi I., Zuo X., Broaddus R., Wu Y., Guan B., Morris J.S., Lippman S.M.: “The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer”. FASEB J., 2007, 21, 743.

[23] Shureiqi I., Jiang W., Fischer S.M., Xu X., Chen D., Lee J.J., et al.: “GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells”. Cancer. Res., 2002, 62, 1178.